Literature DB >> 31256324

Immunological and Clinicopathological Significance of MFG-E8 Expression in Patients with Oral Squamous Cell Carcinoma.

Ayako Okamoto1, Koichi Sakakura1, Hideyuki Takahashi1, Sei-Ichiro Motegi2, Kyoichi Kaira3, Yuki Yokobori-Kuwabara1, Osamu Ishikawa2, Kazuaki Chikamatsu4.   

Abstract

Milk fat globule-epidermal growth factor 8 (MFG-E8) is a glycoprotein secreted by the activated macrophages and acts as a bridge between apoptotic cells and phagocytes. Aside from macrophages, a variety of malignant cells also express MFG-E8. The objective of this study is to elucidate the clinical relevance and significance of MFG-E8 in the tumor microenvironment (TME) of patients with oral squamous cell carcinoma (OSCC). We investigated MFG-E8 expression in 74 patients with OSCC by immunohistochemistry and evaluated the relationship between MFG-E8 expression and various clinicopathological factors including immune cell infiltration. MFG-E8 expression was detected in 34 of 74 (45.9%) patients with OSCC and a significant correlation was observed with levels of infiltrating T cells, macrophages, and immunosuppressive M2 macrophages. Furthermore, MFG-E8 expression was also associated with clinical stage, lymphatic/vascular invasion, and Ki-67+ tumor cells but not with survival. Our results suggest that MFG-E8 may play an important role in shaping the immune suppressive network in TME as well as tumor progression.

Entities:  

Keywords:  Immune suppression; Milk fat globule-epidermal growth factor 8 (MFG-E8); Oral squamous cell carcinoma (OSCC); Tumor microenvironment (TME)

Year:  2019        PMID: 31256324     DOI: 10.1007/s12253-019-00692-3

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  1 in total

Review 1.  Lactadherin: From a Well-Known Breast Tumor Marker to a Possible Player in Extracellular Vesicle-Mediated Cancer Progression.

Authors:  Eduardo Durán-Jara; Tamara Vera-Tobar; Lorena De Lourdes Lobos-González
Journal:  Int J Mol Sci       Date:  2022-03-31       Impact factor: 5.923

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.